-

04:59:06 PM

REGN Stock News

REGN - Regeneron Pharmaceuticals, Inc.

06/24/22 7:31 AM

Nasdaq : REGN, NTLA

clinical trial

Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose

Serum TTR reductions were sustained at all doses tested with follow-up now reaching 12 months in the 0.1 and 0.3 mg/kg and six months in the 0.7 and 1.0 mg/kg cohortsPharmacokinetic modeling and simulation indicated that an 80 mg fixed dose provides similar exposure to the 1.0 mg/kg dose, where

RHEA-AI

neutral

06/07/22 4:44 PM

Nasdaq : SNY, REGN

fda approval

FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis

Children treated with Dupixent and topical corticosteroids (TCS) achieved clearer skin, experienced significantly improved overall disease severity and significantly reduced itch compared to TCS alone at week 16 in a Phase 3 trialLong-term safety data from a 52-week open-label extension trial in

RHEA-AI

neutral

06/02/22 7:30 AM

Nasdaq : REGN

Regeneron Strengthens Commitment to Oncology through Purchase of Sanofi's Stake in the Regeneron and Sanofi Collaboration on Libtayo® (cemiplimab), a PD-1 Inhibitor Approved for Multiple Forms of Cancer

Regeneron will secure global rights to Libtayo from Sanofi in exchange for upfront payment of $900 million, plus royalties and potential future milestone payments18 different investigational treatment combinations with Libtayo currently being evaluated in 22 clinical trialsRegeneron will host an

RHEA-AI

positive

05/31/22 8:31 AM

Nasdaq : REGN

acquisition

Regeneron Completes Acquisition of Checkmate Pharmaceuticals

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has successfully acquired Checkmate

RHEA-AI

positive

05/31/22 12:59 AM

Nasdaq : REGN, SNY

FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults with Prurigo Nodularis

Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approvedRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration

RHEA-AI

neutral

05/21/22 7:00 AM

Nasdaq : REGN

clinical trial

Evkeeza® (evinacumab) Phase 3 Trial Demonstrates 48% LDL-C Reduction in Children with Ultra-rare Form of High Cholesterol

Children already on other lipid-lowering therapies entered the trial with dangerously high LDL-C (264 mg/dL on average), and 79% saw their LDL-C reduced by at least half at 24 weeksFDA submission planned by end of 2022Regeneron Pharmaceuticals,

RHEA-AI

neutral

05/20/22 3:15 PM

Nasdaq : REGN, SNY

fda approval

FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis

Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action dateDupixent 300 mg weekly significantly improved signs and

RHEA-AI

positive

05/17/22 7:00 AM

Nasdaq : REGN

Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur

Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc. with participation from existing

RHEA-AI

neutral

05/13/22 1:13 PM

Nasdaq : REGN

High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair

Regeneron Pharmaceuticals, Inc. and Society for Science (the

RHEA-AI

positive

05/13/22 11:52 AM

Nasdaq : REGN

High School Scientists from Around the World Win Nearly $8M in Awards, Scholarships at Regeneron International Science and Engineering Fair

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for

RHEA-AI

positive

1 2 3 4 5 6 7 8 9 10 Next

REGN Data

Websitewww.regeneron.com
CeoLeonard Schleifer
Security nameRegeneron Pharmaceuticals, Inc.
Issue typecs
Sic code2834
Employees9123
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address777 Old Saw Mill River Rd
StateNew York
CityTarrytown
Zip10591-6717
CountryUnited States
Phone19148477000

About Regeneron Pharmaceuticals, Inc.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.